Independent Portfolio Consultants buys $2,334,461 stake in Amgen (AMGN)

Amgen (AMGN) : Independent Portfolio Consultants scooped up 2,335 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 14,328 shares of Amgen which is valued at $2,334,461.Amgen makes up approximately 0.71% of Independent Portfolio Consultants’s portfolio.

Other Hedge Funds, Including , Sonora Investment Management sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 70 shares of AMGN which is valued $11,405.Jacobs Coca boosted its stake in AMGN in the latest quarter, The investment management firm added 2,270 additional shares and now holds a total of 37,783 shares of Amgen which is valued at $6,064,927. Amgen makes up approx 1.39% of Jacobs Coca’s portfolio.Exxonmobil Investment Management Inc Tx boosted its stake in AMGN in the latest quarter, The investment management firm added 11,337 additional shares and now holds a total of 194,453 shares of Amgen which is valued at $31,326,378. Amgen makes up approx 0.65% of Exxonmobil Investment Management Inc Tx’s portfolio.Ct Financial Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 550 additional shares and now holds a total of 14,481 shares of Amgen which is valued at $2,332,889. Amgen makes up approx 1.46% of Ct Financial Advisors’s portfolio.

Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.